ESMO22: leczenie raka jajnika. Wyniki badań SOLO-1 i PAOLA-1

(4:51)

Immunoterapia i leczenie celowane w mCRC | Lekarz Dustin Deming | ESMO22 Pensylwania

(1:35)

#ESMO22 Najważniejsze informacje dotyczące atezolizumabu pierwszego rzutu u chorych na NSCLC niekwalifikujących się do leczenia platyną: badanie IPSOS

(2:30)

#ESMO22 Najważniejsze informacje dotyczące pembrolizumabu w skojarzeniu z CRT u chorych z miejscowo zaawansowanym HNSCC: badanie KEYNOTE-412

(2:17)

#ESMO22 Highlights on nirogacestat in patients with progressing desmoid tumours: The DeFi study

(2:56)

#ESMO22 Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study

(2:46)

Updates in Upper GI Cancer | Florian Lordick, MD | ESMO22 Pennsylvania

(4:21)

New Classifications and Staging in Breast Cancer | Manisha Bahl, MD | ESMO22 Pennsylvania

(51)

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

(2:37)

How to Treat Early Relapses in Lymphoma | Boyu Hu, MD | ESMO22 Colorado

(2:28)

#ESMO22 Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD

(2:21)

Developments in Immunotherapy \u0026 Targeted Treatment for mNSCLC | Tejas Patil, MD | ESMO22 Colorado

(3:26)

#ESMO22 Highlights on the efficacy and safety of fruquintinib in refractory mCRC: The FRESCO-2 study

(3:35)

Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 Colorado

(3:42)

Diagnostics in Early BC—Who, Which Test, When | Maysa Abu-Khalaf, MD | ESMO22 Pennsylvania

(2:26)

ESMO22: Ben Schlechter, MD | Dana-Farber Cancer Institute

(2:3)

ESMO 2022 Highlights

(1:)

#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02

(2:58)

#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study

(2:35)

Updates in kidney cancer at ESMO 2022

(59)

Immunotherapy Activates the Immune System

(9)

Metastatic breast cancer at ESMO 2022: TROPiCS02, MONARCH 3 and SYNERGY

(5:37)